A Canadian researcher has won a 2025 Breakthrough Prize in Life Sciences for discovering the GLP-1 hormone used in diabetes ...

At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients on Medicaid. Indiana is not ...

The Centers for Medicare Medicaid Services (CMS) announced it will not proceed with a Biden administration proposal to expand ...

The Centers for Medicare & Medicaid Services will not cover drugs when exclusively used for weight loss, like Ozempic or Wegovy, the Trump administration announced.

Advances recognized by science’s most lucrative awards include Large Hadron Collider experiments and groundbreaking ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Trump administration has chosen not to finalize a rule proposed by the Biden administration that would have allowed ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded coverage of costly anti-obesity drugs to more than 7 million Americans on ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

Trump administration rejects a Biden plan to expand Medicare coverage of weight-loss drugs such as Zepbound and Wegovy.

Shares of Eli Lilly, the seller of Zepbound, were down 2.7% to $718.50 after the close on Friday. Novo Nordisk, the maker of Wegovy, saw its stock decline 1.4% to $61.67. Shares of Hims & Hers, a ...

The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.